Novare Capital Management LLC Acquires 4,799 Shares of Eli Lilly and Company $LLY

Novare Capital Management LLC grew its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 93.8% in the 1st quarter, HoldingsChannel reports. The firm owned 9,915 shares of the company’s stock after acquiring an additional 4,799 shares during the quarter. Novare Capital Management LLC’s holdings in Eli Lilly and Company were worth $9,119,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently modified their holdings of LLY. Summit Wealth Partners LLC raised its stake in shares of Eli Lilly and Company by 26.8% in the first quarter. Summit Wealth Partners LLC now owns 331 shares of the company’s stock valued at $304,000 after buying an additional 70 shares during the period. Harbour Wealth Management Group Inc. boosted its holdings in Eli Lilly and Company by 3.3% in the 1st quarter. Harbour Wealth Management Group Inc. now owns 468 shares of the company’s stock valued at $431,000 after purchasing an additional 15 shares during the period. Elk River Wealth Management LLC grew its stake in Eli Lilly and Company by 5.0% in the 1st quarter. Elk River Wealth Management LLC now owns 7,900 shares of the company’s stock worth $7,267,000 after buying an additional 379 shares in the last quarter. Atlas Brown Inc. grew its position in Eli Lilly and Company by 1.5% in the first quarter. Atlas Brown Inc. now owns 2,005 shares of the company’s stock worth $1,844,000 after acquiring an additional 30 shares in the last quarter. Finally, Matthew Goff Investment Advisor LLC boosted its holdings in shares of Eli Lilly and Company by 24.3% in the 1st quarter. Matthew Goff Investment Advisor LLC now owns 1,930 shares of the company’s stock worth $1,775,000 after purchasing an additional 377 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 0.8%

Eli Lilly and Company stock opened at $1,110.37 on Wednesday. The stock has a fifty day moving average of $1,022.46 and a 200 day moving average of $1,018.08. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,182.73. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The stock has a market cap of $1.05 trillion, a PE ratio of 39.44, a price-to-earnings-growth ratio of 1.20 and a beta of 0.53.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The business had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm’s revenue was up 55.5% on a year-over-year basis. During the same period in the prior year, the company earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, sell-side analysts predict that Eli Lilly and Company will post 35.8 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s payout ratio is currently 24.58%.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly expanded its neuroscience pipeline with a new research collaboration with BioArctic, combining Lilly’s drug candidate with BioArctic’s BrainTransporter technology to develop a potential treatment for neurodegenerative disease; the deal included a $30 million upfront payment and reinforces Lilly’s pipeline growth strategy. BioArctic and Lilly sign research and collaboration agreement combining Lilly compound with BioArctic’s BrainTransporter™ technology
• Positive Sentiment: The company was also cleared to advance its planned acquisition of Centessa by the High Court of Justice of England and Wales, supporting Lilly’s efforts to broaden its drug portfolio and add to future growth drivers. Acquisition of Centessa by Lilly Approved by the High Court of Justice of England and Wales
• Positive Sentiment: Reuters reported that Lilly expects to launch its weight-loss pill in Europe and Britain in late 2026 or early 2027, extending the commercial opportunity for its obesity franchise outside the U.S. Eli Lilly says Trump pricing policy will affect obesity drug launches in Europe
• Positive Sentiment: Analysts and commentary continued to highlight Lilly’s strong growth profile, including surging sales for Mounjaro and Zepbound and optimism around the still-expanding GLP-1 market, which supports the stock’s premium valuation. Eli Lilly (LLY) Opens Data Center to Smaller Biotech Firms as It Chases Drug Discoveries
• Neutral Sentiment: Lilly declared a quarterly dividend of $1.73 per share, a routine capital return update that is supportive but not likely to move the stock materially on its own. Lilly declares third-quarter 2026 dividend
• Neutral Sentiment: The healthcare sector itself was firmer in afternoon trading, providing a favorable backdrop for Eli Lilly alongside broader rotation into defensive/healthcare names. Sector Update: Healthcare Stocks Advance in Afternoon Trading
• Neutral Sentiment: Some headlines noted investor enthusiasm around Lilly’s stock and its GLP-1 leadership, but these were largely commentary pieces rather than new fundamental catalysts. Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
• Negative Sentiment: One Reuters report said Trump pricing policy could complicate Lilly’s obesity-drug launches in Europe, creating some regulatory and pricing uncertainty for an important growth franchise. Eli Lilly says Trump pricing policy will affect obesity drug launches in Europe

Analysts Set New Price Targets

Several research firms recently commented on LLY. Wall Street Zen raised shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 2nd. HSBC lowered Eli Lilly and Company from a “hold” rating to a “reduce” rating and dropped their price target for the stock from $1,070.00 to $850.00 in a research note on Tuesday, March 17th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Eli Lilly and Company in a research report on Monday. Sanford C. Bernstein restated an “outperform” rating on shares of Eli Lilly and Company in a report on Monday, June 8th. Finally, The Goldman Sachs Group restated a “buy” rating and issued a $1,283.00 price target on shares of Eli Lilly and Company in a research note on Friday, May 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $1,230.89.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.